SCHEMBL6492290

SCHEMBL6492290

c1ccc2c(c1)oc1ccc(NC3CCC(C4CCCCC4)CC3)cc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.48
LMNA P02545 3/20 0.48
GAA P10253 4/20 0.43
KMT2A Q03164 6/20 0.41
MEN1 O00255 4/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
NPC1 O15118 4/20 0.41
RAB9A P51151 4/20 0.41
HTT P42858 2/20 0.41
HPGD P15428 4/20 0.40
MAPT P10636 3/20 0.40
TP53 P04637 1/20 0.40
HSD17B10 Q99714 1/20 0.40
SYK P43405 1/20 0.40
ALDH1A1 P00352 3/20 0.40
AHR P35869 2/20 0.38
NR1I2 O75469 1/20 0.38
POLB P06746 1/20 0.38
IDO1 P14902 1/20 0.38
IP6K1 Q92551 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6495251 0.92 KDM4E (0.56) KDM4ELMNAGAAKMT2AMEN1
SCHEMBL6482610 0.92 KDM4E (0.56) KDM4ELMNAGAAKMT2AMEN1
SCHEMBL6495339 0.92 KDM4E (0.56) KDM4ELMNAGAAKMT2AMEN1
SCHEMBL6492312 0.90 KDM4E (0.54) KDM4ELMNAGAAKMT2AMEN1
SCHEMBL6482854 0.83 KDM4E (0.56) KDM4ELMNAGAAKMT2AMEN1
SCHEMBL6483570 0.83 KDM4E (0.56) KDM4ELMNAGAAKMT2AMEN1
SCHEMBL6481111 0.83 SYK (0.43) KDM4ELMNAGAAKMT2AMEN1
SCHEMBL6481790 0.81 HTR6 (0.46) KDM4ELMNAGAAKMT2AMEN1
SCHEMBL6495109 0.81 MEN1 (0.43) KDM4ELMNAGAAKMT2AMEN1
SCHEMBL6491925 0.80 CNR2 (0.42) KDM4ELMNAGAAKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050075332-A1 Tricyclic compounds with antiviral activity WARNER LAMBERT COMPANY 2005-04-07 US claimed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US claimed
EP-1248777-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2002-10-16 EP claimed
WO-2001051479-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2001-07-19 WO claimed
US-20050075332-A1 Tricyclic compounds with antiviral activity WARNER LAMBERT COMPANY 2005-04-07 US disclosed
US-6800656-B2 Tricyclic compounds and method of treating herpes virus WARNER LAMBERT COMPANY 2004-10-05 US disclosed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US disclosed
EP-1248777-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2002-10-16 EP disclosed
WO-2001051479-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2001-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus HDAC8, ZC3HAV1, ZCCHC8 KDM4E 1279/4885LMNA 3647/4885GAA 1524/4885
US-20050075332-A1 Tricyclic compounds with antiviral activity HDAC8, CDK8, ZC3HAV1 KDM4E 1476/4885LMNA 4305/4885GAA 1297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.